Arthritis, psoriatic

definition, 643

hepatitis B vaccine, onset or exacerbation of, 479–480, 492t

Arthritis, reactive

definition, 643

hepatitis B vaccine and, 480–482, 493t

mechanism(s) that may contribute to symptoms of, 481–482

Arthritis, rheumatoid

definition, 644

hepatitis B vaccine, onset or exacerbation of, 482–485, 493t

immune complexes and, 67

mechanism(s) that may contribute to symptoms of, 485

Arthropathy

chronic, in children, MMR vaccine and, 199–200, 220t,

definition, 635

DTaP vaccine and, 567–571, 588t

influenza vaccine, onset or exacerbation of, 384–385, 403t

mechanism(s) that may contribute to symptoms of, 200, 202, 279, 385, 571

in men, MMR vaccine and, 201–204, 220t

varicella vaccine, onset or exacerbation of, 278–279, 284t

ASO4, 59

Assessment of causality

DTaP vaccine

acute disseminated encephalomyelitis, 546–547

anaphylaxis, 563–565

arthropathy, 567–571

ataxia, 544–545

autism, 545–546

Bell’s Palsy, 561–562

chronic inflammatory disseminated polyneuropathy, 558–560

chronic urticaria, 565–566

encephalitis and encephalopathy, 534–537

fibromyalgia, 581

Guillain-Barré syndrome, 557–558

immune thrombocytopenic purpura, 582–584

infantile spasms, 537–539

multiple sclerosis onset in adults, 550–553

multiple sclerosis relapse in adults, 554–555

multiple sclerosis relapse in children, 555–557

myocarditis, 579–580

opsoclonus myoclonus syndrome, 560–561

optic neuritis, 549–550

seizures, 539–544

serum sickness, 566–567

sudden infant death syndrome, 581–582

summary of evidence and causality conclusions, 22t, 585–588t, 683–687t

transverse myelitis, 547–548

type 1 diabetes, 22t, 571–579

hepatitis A vaccine

acute disseminated encephalomyelitis, 423–424

anaphylaxis, 428–429

autoimmune hepatitis, 429–430

Bell’s palsy, 427–428

chronic inflammatory disseminated polyneuropathy, 427

Guillain-Barré syndrome, 426

multiple sclerosis, 425

summary of evidence and causality conclusions, 4311, 680–681t

transverse myelitis, 424–425

hepatitis B vaccine

acute disseminated encephalomyelitis, 440–442

anaphylaxis, 468–469

brachial neuritis, 467–468

chronic inflammatory disseminated polyneuropathy, 466–467

encephalitis and encephalopathy, 437–438

erythema nodosum, 469–471

fibromyalgia, 490

first demyelinating event in adults, 458–464

first demyelinating event in children, 464–465

Guillain-Barré syndrome, 465–466

juvenile idiopathic arthritis, onset or exacerbation, 485–488



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement